Kenvue/kimberly-clark Deal not in Jeopardy Despite Tylenol Ruling

Dow Jones07-14

1450 ET - A ruling that litigation against Kenvue over alleged links between Tylenol and neurodevelopmental disorders can continue is a negative for the company, but probably doesn't jeopardize its acquisition by Kimberly-Clark, BNP Paribas analysts write in a note. They keep their neutral rating on the stock, "given the potential material liabilities if further proceedings result in a negative outcome for Kenvue." Still, they say new research supports Kenvue's view that no causal link exists between acetaminophen and neurodevelopmental disorders, especially ADHD and autism. "Importantly, we do not expect today's decision to derail the Kimberly-Clark acquisition deal," the analysts write. The ruling takes no view on the reliability of plaintiffs' expert witnesses that argue for a link, the analysts point out, but says those questions ought to be decided by a jury. Kenvue falls 1.8%; Kimberly-Clark is off 2.5%. (elias.schisgall@wsj.com)

(END) Dow Jones Newswires

July 13, 2026 14:50 ET (18:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651814965?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 02:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651814965","market":"sg","top_or_hot":-1,"title":"Kenvue/kimberly-clark Deal not in Jeopardy Despite Tylenol Ruling","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1450 ET - A ruling that litigation against Kenvue over alleged links between Tylenol and neurodevelopmental disorders can continue is a negative for the company, but probably doesn't jeopardize its acquisition by Kimberly-Clark, BNP Paribas analysts write in a note. They keep their neutral rating on the stock, \"given the potential material liabilities if further proceedings result in a negative outcome for Kenvue.\" Still, they say new research supports Kenvue's view that no causal link exists between acetaminophen and neurodevelopmental disorders, especially ADHD and autism. \"Importantly, we do not expect today's decision to derail the Kimberly-Clark acquisition deal,\" the analysts write. The ruling takes no view on the reliability of plaintiffs' expert witnesses that argue for a link, the analysts point out, but says those questions ought to be decided by a jury. Kenvue falls 1.8%; Kimberly-Clark is off 2.5%. (elias.schisgall@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 13, 2026 14:50 ET (18:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kenvue/kimberly-clark Deal not in Jeopardy Despite Tylenol Ruling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKenvue/kimberly-clark Deal not in Jeopardy Despite Tylenol Ruling\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-14 02:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1450 ET - A ruling that litigation against Kenvue over alleged links between Tylenol and neurodevelopmental disorders can continue is a negative for the company, but probably doesn't jeopardize its acquisition by Kimberly-Clark, BNP Paribas analysts write in a note. They keep their neutral rating on the stock, \"given the potential material liabilities if further proceedings result in a negative outcome for Kenvue.\" Still, they say new research supports Kenvue's view that no causal link exists between acetaminophen and neurodevelopmental disorders, especially ADHD and autism. \"Importantly, we do not expect today's decision to derail the Kimberly-Clark acquisition deal,\" the analysts write. The ruling takes no view on the reliability of plaintiffs' expert witnesses that argue for a link, the analysts point out, but says those questions ought to be decided by a jury. Kenvue falls 1.8%; Kimberly-Clark is off 2.5%. (elias.schisgall@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 13, 2026 14:50 ET (18:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3T34201.USD","symbol_name":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651814965","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651814965","pubTimestamp":1783968600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1450 ET - A ruling that litigation against Kenvue over alleged links between Tylenol and neurodevelopmental disorders can continue is a negative for the company, but probably doesn't jeopardize its acquisition by Kimberly-Clark, BNP Paribas analysts write in a note. They keep their neutral rating on the stock, \"given the potential material liabilities if further proceedings result in a negative outcome for Kenvue.\" Still, they say new research supports Kenvue's view that no causal link exists between acetaminophen and neurodevelopmental disorders, especially ADHD and autism. \"Importantly, we do not expect today's decision to derail the Kimberly-Clark acquisition deal,\" the analysts write. The ruling takes no view on the reliability of plaintiffs' expert witnesses that argue for a link, the analysts point out, but says those questions ought to be decided by a jury. Kenvue falls 1.8%; Kimberly-Clark is off 2.5%.  Dow Jones NewswiresJuly 13, 2026 14:50 ET Copyright  2026 Dow Jones & Compa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","RSPS":"Invesco S&P 500 Equal Weight Consumer Staples ETF","KVUE":"Kenvue Inc","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","KMB":"金佰利","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4018":"居家用品","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","BK4504":"桥水持仓","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4183":"个人用品","BK4588":"碎股","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC"},"translate_title":"尽管泰诺做出裁决，Kenvue/kimberly-clark 交易并未受到威胁","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KMB":0.9,"KVUE":0.9,"RSPS":0.6},"content_text":"1450 ET - A ruling that litigation against Kenvue over alleged links between Tylenol and neurodevelopmental disorders can continue is a negative for the company, but probably doesn't jeopardize its acquisition by Kimberly-Clark, BNP Paribas analysts write in a note. They keep their neutral rating on the stock, \"given the potential material liabilities if further proceedings result in a negative outcome for Kenvue.\" Still, they say new research supports Kenvue's view that no causal link exists between acetaminophen and neurodevelopmental disorders, especially ADHD and autism. \"Importantly, we do not expect today's decision to derail the Kimberly-Clark acquisition deal,\" the analysts write. The ruling takes no view on the reliability of plaintiffs' expert witnesses that argue for a link, the analysts point out, but says those questions ought to be decided by a jury. Kenvue falls 1.8%; Kimberly-Clark is off 2.5%. (elias.schisgall@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  July 13, 2026 14:50 ET (18:50 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651814965","isCrawlerRequest":true}